From Generics to Innovation: The Changing Landscape of India’s Pharmaceutical Industry

Market pressures, regulatory reforms, AI-driven innovation, and emerging opportunities shaping the future of Indian pharma

Market Performance and Pricing Pressures

• Indian pharma companies faced pricing pressure in Q3FY26, especially in US generics. ​
• Competition, channel consolidation, and complex therapies aimed to offset generic market weaknesses. ​
• Analysts predict US generics prices will remain under pressure through FY27, with gradual shift to niche innovative products. ​
• Companies like Sun Pharma saw 0.6% growth in US formulation sales; Dr Reddy’s and Cipla experienced declines of 12% and 22%, respectively.
• Alembic outperformed with 6% growth, supported by product launches and volume expansion. ​

Regulatory and Industry Challenges

• Indian regulators aim to expedite drug approvals, with move to reduce testing and review timelines by June 2026.
• Clinical trial delays and slow domestic acceptance hinder innovation; companies often conduct early studies overseas. ​
• India’s clinical trial share fell from 11% in 2019 to 3% in 2025. ​
• Regulatory reforms include waivers for animal testing, faster approval processes, and amendments to clinical trial rules.
• Strengthening of regulatory agencies like CDSCO and establishment of clinical trial networks are ongoing.

Innovation and R&D

• Industry leaders emphasize the need for faster, predictable regulation to boost innovation. ​
• India aims to transition from generics to higher-value innovation, with focus on complex biologics, biosimilars, and niche therapies. ​
• China’s rapid approval and domestic market growth are benchmarks; India seeks similar agility.
• Indian companies are investing in R&D, with some out-licensing deals and out-sourcing to global markets. ​
• AI integration in drug discovery, clinical trials, and manufacturing is gaining momentum, improving efficiency and reducing timelines. ​
• Companies like MSD and Takeda are embedding AI into workflows; AI is used for disease detection, data analysis, and regulatory documentation. ​

Market Trends and Product Launches

• US market accounted for 27.5% of Sun Pharma’s sales; new launches include Unloxcyt and peptide products. ​
• Dr Reddy’s launched four new ANDAs; Cipla’s US business declined 22% due to supply chain issues.
• Alembic’s US generics grew 6% to ₹553 crore, supported by product launches and volume growth. ​
• India’s pharma exports to West Asia faced disruptions due to geopolitical conflicts, with higher freight and input costs.
• Semaglutide and tirzepatide branded generics are entering India, with prices 50-60% lower than innovator drugs, expanding the market. ​

Industry Restructuring and Mergers

• MNCs like Novartis are trimming India portfolios, focusing on innovative drugs; Novartis to exit India’s listed unit in $159 million deal. ​
• Companies like Sanofi divested core portfolios; Dr Reddy’s and Eli Lilly made strategic acquisitions and partnerships. ​
• MNC market share declined; domestic firms are strengthening through innovation and regulatory compliance.
• Novartis licensed manufacturing rights to Cipla; Indian firms are increasingly R&D-driven, with investments in biologics and biosimilars. ​

Regulatory and Policy Reforms

• The government aims to reduce approval timelines, streamline testing, and promote domestic manufacturing.
• Amendments to NDCT Act and clinical trial rules are designed to ease regulatory burdens.
• Policies to promote biologics, biosimilars, and complex generics are prioritized.
• Efforts include waivers for efficacy data, animal testing, and faster clinical trial approvals to boost innovation. ​

Medical Devices and Import Policies

• Domestic medical device manufacturers oppose easing import restrictions on refurbished equipment due to safety concerns. ​
• The government formed a panel to evaluate safety and lifespan of refurbished devices. ​
• Importers support policy if OEM accountability and patient safeguards are ensured. ​
• India remains heavily import-dependent for medical devices; unregulated trade of pre-owned equipment estimated at ₹12,000-₹15,000 crore annually. ​

Palliative and Supportive Care

• India faces rising chronic diseases and aging population, emphasizing the need for integrated palliative care. ​
• A report highlights uneven implementation of palliative policies; access is limited mainly to urban centers. ​
• Supportive care improves symptom management, emotional well-being, and reduces hospital stays. ​
• Experts advocate for formal recognition, early referral, insurance coverage, and training to expand services nationwide.

Biopharma and Biosimilars

• India’s biopharma sector is gaining importance, with a focus on biologics, biosimilars, and complex therapies. ​
• Budget 2026 allocates ₹10,000 crore for biologics and biosimilars ecosystem development. ​
• Regulatory reforms aim to waive efficacy data and animal testing, reducing approval costs and timelines.
• India aims to become a global hub for biologics, leveraging its large patient pool and R&D capabilities. ​

Industry Outlook and Future Trends

• Indian pharma industry must accelerate regulatory reforms, innovation, and digital adoption to compete globally.
• AI-driven drug discovery, clinical trials, and manufacturing are transforming the sector. ​
• Companies are investing in capacity expansion, complex formulations, and high-value therapies. ​
• The sector faces challenges from geopolitical conflicts, supply chain disruptions, and regulatory delays but is poised for growth through innovation and policy support.